Potassium Disturbances

Potassium is the major intracellular cation in the body, obtained from dietary sources such as fruit, vegetables, fish, and meat, with a typical daily intake of 50-100 mmol. Normal plasma potassium is 3.5-5 mmol/L, and this narrow range is maintained by both total-body potassium stores and rapid, reversible shifts of potassium between the intracellular and extracellular compartments — driven by insulin, beta-adrenergic tone, and acid-base status — so a single plasma value can reflect either a true total-body deficit/excess or a transient shift, and management differs depending on which is present. Hyperkalemia (plasma potassium over 5 mmol/L: mild 5-6, moderate 6.1-6.5, severe over 6.5 mmol/L) and hypokalemia (plasma potassium under 3.5 mmol/L: mild 3-3.5, moderate 2.5-3, severe under 2.5 mmol/L) both matter clinically for the same core reason — either direction can produce potentially fatal cardiac arrhythmias, alongside musculoskeletal, neurologic, and psychiatric complications — and the urgency of treatment is driven as much by ECG findings, rate of change, and concurrent risk factors as by the lab value itself.^[1]

Both directions of potassium disturbance can be entirely asymptomatic and detected only on routine bloodwork, especially at mild severity — clinical suspicion and severity staging both matter for deciding how urgently to act.^[2]

History

• Directed at etiology — see the causes listed in Risk Factors for each direction.
• Ask about muscle weakness, paresthesias, palpitations, and features suggesting the specific mechanisms above (diuretic or supplement use, GI losses, dietary intake, licorice or herbal supplement use, family history).

Physical examination

• Cardiac rhythm, muscle strength, and paresthesias.
• Blood pressure — consider hyperaldosteronism when hypokalemia coexists with hypertension.
• Extracellular fluid volume (ECFV) status, assessed indirectly since total body sodium heavily influences potassium handling: edema, hypertension, elevated jugular venous pressure (JVP), ascites, and pleural effusions suggest ECFV expansion; poor skin turgor, hypotension (especially a postural drop), and decreased JVP suggest ECFV contraction.

ECG

Obtain when clinically necessary — severe hyperkalemia or hypokalemia, or any symptomatic presentation. In hyperkalemia, the classic progression is peaked T waves, then PR-interval prolongation and P-wave flattening/loss, then QRS widening, then a sine-wave pattern preceding ventricular fibrillation or asystole — though isolated peaked T waves may not be significant, and the prognostic value of ECG changes overall is not absolute. In hypokalemia, look for U waves, T-wave flattening, and ST-segment changes, which signal increased arrhythmia risk, including torsades de pointes.

Laboratory testing

• Urea, creatinine, sodium, potassium, chloride, and glucose.
• Magnesium — essential in refractory hypokalemia, especially in patients at risk of hypomagnesemia (alcohol use disorder, diarrhea, or use of cisplatin, diuretics, or a proton pump inhibitor).
• Arterial or venous blood gas, or total CO2 — systemic pH has a major effect on transcellular potassium movement.
• Urine sodium, potassium, chloride, and osmolality to calculate the transtubular potassium gradient (TTKG) and the potassium-creatinine ratio, and a 24-hour urine collection for sodium, potassium, and creatinine in select cases.
• Aldosterone, cortisol, renin, adrenal disease screening, TSH (thyrotoxicosis), kidney ultrasound, and renal artery imaging in select cases where the cause remains unclear after initial workup.

These further investigations are for identifying an unclear underlying cause, not for guiding acute treatment — do not delay emergency stabilization while awaiting results.^[4]

• Prevent life-threatening cardiac arrhythmias and preserve neuromuscular conduction.
• Re-establish normal total-body potassium stores and prevent ongoing loss or accumulation.
• Identify and correct the underlying cause rather than treating the lab value in isolation.
• In hyperkalemia specifically: avoid iatrogenic hypoglycemia during insulin-based redistribution therapy.
• In hypokalemia specifically: correct any concurrent magnesium deficit, since potassium correction is often incomplete or transient until magnesium is also normalized.

Pregnancy

Potassium disturbances are assessed and treated in pregnancy using the same severity thresholds, ECG-driven urgency, and emergency-stabilization sequence as in a non-pregnant adult — there is no pregnancy-specific dose adjustment for calcium, insulin/dextrose, furosemide, or potassium chloride. Normal pregnancy involves mild physiologic changes in potassium handling from expanded plasma volume and altered renin-angiotensin-aldosterone activity, so a mildly low-normal potassium in an otherwise well pregnant patient does not automatically require treatment. ACE inhibitors and ARBs — already relevant hyperkalemia-causing drugs outside pregnancy — are separately contraindicated in pregnancy for teratogenicity reasons and should already be held regardless of the potassium indication.

Breastfeeding

Calcium, insulin/dextrose, furosemide, salbutamol, and standard oral/IV potassium replacement are all considered compatible with breastfeeding at usual doses. Data on the newer potassium binders (patiromer, sodium zirconium cyclosilicate) in lactation are limited, though systemic absorption from either agent is expected to be minimal given their non-absorbed, gut-acting mechanism.

Pediatrics

Potassium replacement in children is weight-based and must be individualized under pediatric or pediatric nephrology guidance — the adult mmol-based dosing and infusion-rate limits in this chapter's Drug Tables must not be extrapolated directly to a child. Not established in this source for routine pediatric dosing.

Renal impairment

Kidney failure is one of the most common causes of hyperkalemia and requires earlier, more aggressive treatment given impaired renal potassium excretion; dialysis is the definitive treatment for severe or refractory cases. Sodium zirconium cyclosilicate and patiromer are both effective for maintaining normokalemia in chronic kidney disease, including in patients continued on a RAAS inhibitor; dose-related edema with sodium zirconium cyclosilicate can usually be managed with dose reduction or diuretic therapy. Potassium-sparing diuretics should generally be avoided in significant kidney impairment given the markedly increased hyperkalemia risk.

Older adults and hepatic impairment

Older adults are at increased hyperkalemia risk with ACE inhibitor/ARB and potassium-sparing diuretic combinations — monitor closely (see Monitoring and Follow-up). In hepatic insufficiency, correct hypokalemia promptly, since it increases the risk of hepatic encephalopathy; IV replacement is a recognized urgent indication in this population when oral intake is inadequate.^[4]

Monitor plasma potassium frequently during any active correction — after each 20-40 mmol IV dose of potassium chloride in hypokalemia, and repeatedly through the elimination phase of hyperkalemia treatment (loop diuretic, binder, or dialysis). Monitor plasma glucose closely during insulin-based redistribution therapy for hyperkalemia. Use continuous ECG monitoring throughout IV calcium administration and during any potassium infusion above the routine peripheral rate limit.

After starting or changing the dose of a hyperkalemia-inducing medication — particularly an ACE inhibitor, ARB, or potassium-sparing diuretic, and especially the combination of a RAAS inhibitor with spironolactone — check potassium at 3 and 7 days, then check creatinine and potassium at 1 week and 4 weeks, and every 6 months thereafter if stable. This monitoring schedule matters most in patients already at elevated hyperkalemia risk: kidney failure, older age, and cardiac insufficiency.^[4]

For chronic or recurrent hyperkalemia, focus follow-up on the underlying cause or pathophysiologic mechanism rather than repeated acute treatment — the same agents used acutely (diuretics, sodium bicarbonate, potassium binders) are also used for ongoing chronic management.

1. For hyperkalemia not responding as expected: confirm adherence to the dietary and medication changes already made, and rule out ongoing potassium input — GI bleeding, resolving hematoma, hemolysis, tumor lysis, or rhabdomyolysis.
2. Reassess kidney function — worsening kidney failure both raises potassium and blunts the response to loop diuretics and binders.
3. Escalate elimination therapy — add or switch to a potassium binder, and move to dialysis without further delay if hyperkalemia is severe, refractory, or accompanied by ongoing large potassium input.
4. For hypokalemia refractory to potassium repletion alone: check and correct magnesium — this is the single most common reason apparently adequate potassium replacement fails to raise the level.
5. Reassess for ongoing renal or GI losses, and review whether a potassium-wasting diuretic or another causative drug is still being given unnecessarily.
6. If hypokalemia is refractory and accompanied by hypertension, investigate for mineralocorticoid excess (e.g., primary aldosteronism) rather than continuing to escalate potassium dosing alone.

• Delaying IV calcium while waiting on additional labs when ECG changes are already present — calcium is a bedside, immediate-action drug.
• Giving the dextrose component of insulin/dextrose therapy too quickly — an acute rise in plasma tonicity can transiently raise, not lower, plasma potassium; give over at least 5 minutes.
• Relying on nebulized salbutamol alone as the sole hyperkalemia therapy — response is variable, and roughly half of patients with chronic kidney failure are relatively resistant to the nebulized route.
• Mixing calcium and sodium bicarbonate in the same IV line — they are incompatible and will precipitate.
• Infusing IV potassium chloride faster than the peripheral safety limit without central access and continuous ECG monitoring — risks both arrhythmia and vein sclerosis.
• Combining an oral potassium supplement with a potassium-sparing diuretic without frequent monitoring — a well-recognized cause of severe, sometimes unexpected hyperkalemia.
• Treating hypokalemia with potassium alone while ignoring a concurrent magnesium deficit — correction will be incomplete or transient.
• Treating a hyperkalemic lab result without considering pseudohyperkalemia (hemolysis, thrombocytosis, or leukocytosis) first, especially when the result doesn't fit the clinical picture.
• Correcting severe hypokalemia with concurrent hyponatremia too quickly with potassium chloride — both cations count toward total body tonicity, so rapid potassium correction can rapidly correct the hyponatremia as well and precipitate osmotic demyelination.
• In diabetic ketoacidosis, giving insulin or bicarbonate before addressing potassium depletion — both agents can worsen hypokalemia that is often already present.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Beta2-Adrenergic Agonists

Adjunct redistribution therapy for hyperkalemia.

Loop Diuretics

Potassium elimination via the kidney, hyperkalemia.

Electrolytes — Membrane Stabilization and Redistribution

For hyperkalemia with ECG changes or metabolic acidosis.

Insulin

Redistribution, 1st-choice agent for hyperkalemia.

Potassium-Binding Agents

Elimination-phase therapy for hyperkalemia; effectiveness of the older cation-exchange resins is debated, and a concurrent laxative effect may account for much of their apparent benefit.

Potassium Supplements, Intravenous

Reserve for urgent hypokalemia correction or inability to tolerate oral replacement.

Potassium Supplements, Oral

Preferred route whenever the GI tract is usable and urgent correction is not required.

Potassium-Sparing Diuretics

Used for increased kidney potassium losses (e.g., hyperaldosteronism, concomitant use of other diuretics); also useful for magnesium conservation. The most frequent and serious side effect of every agent in this class is hyperkalemia — avoid in kidney or adrenal insufficiency, older adults, patients with diabetes, and patients already taking another potassium-raising drug (see Risk Factors).